Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1951 8
1952 30
1953 10
1954 6
1955 1
1956 5
1957 2
1958 7
1959 1
1961 2
1962 2
1963 1
1964 5
1965 64
1966 96
1967 110
1968 118
1969 180
1970 179
1971 287
1972 263
1973 183
1974 103
1975 105
1976 101
1977 89
1978 122
1979 139
1980 85
1981 124
1982 135
1983 147
1984 168
1985 166
1986 170
1987 268
1988 431
1989 582
1990 614
1991 638
1992 760
1993 783
1994 812
1995 1550
1996 2334
1997 2552
1998 3338
1999 3757
2000 4067
2001 4532
2002 5029
2003 5443
2004 5851
2005 6516
2006 6980
2007 7156
2008 7602
2009 7691
2010 8013
2011 8276
2012 8655
2013 9225
2014 9887
2015 9814
2016 9644
2017 9381
2018 8719
2019 3940
2020 99
Text availability
Article attribute
Article type
Publication date

Search Results

154,252 results
Results by year
Filters applied: . Clear all
Page 1
Proton pump inhibitors: use and misuse in the clinical setting.
Savarino V, et al. Expert Rev Clin Pharmacol 2018 - Review. PMID 30295105
The introduction of proton pump inhibitors (PPIs) into clinical practice has greatly improved our therapeutic approach to acid-related diseases for their efficacy and safety. ...Expert Commentary: Despite the above well-defined indications, however, the use of PPIs continues to grow every year in both western and eastern countries and the endless expansion of the PPI market has created important problems for many regulatory authorities for two relevant features: the progressive increase of the costs of therapy and the greater potential harms for the patients. ...
The introduction of proton pump inhibitors (PPIs) into clinical practice has greatly improved our therapeutic approach to acid …
ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Intracellular signaling pathways: tyrosine kinase and mTOR inhibitors).
Reinwald M, et al. Clin Microbiol Infect 2018 - Review. PMID 29454849 Free article.
SOURCES: Computer-based Medline searches with MeSH terms pertaining to each agent or therapeutic family. CONTENT: Although BCR-ABL tyrosine kinase inhibitors modestly increase the overall risk of infection, dasatinib has been associated with cytomegalovirus and hepatitis B virus reactivation. BRAF/MEK kinase inhibitors do not significantly affect infection susceptibility. The effect of Bruton tyrosine kinase inhibitors (ibrutinib) among patients with B-cell malignancies is difficult to distinguish from that of previous immunosuppression. ...
SOURCES: Computer-based Medline searches with MeSH terms pertaining to each agent or therapeutic family. CONTENT: Although BCR-ABL ty …
Triple negative breast cancer: Emerging therapeutic modalities and novel combination therapies.
Lee A and Djamgoz MBA. Cancer Treat Rev 2018 - Review. PMID 29202431
Triple negative breast cancer (TNBC) is a complex and aggressive subtype of breast cancer which lacks oestrogen receptors, progesterone receptors and HER2 amplification, thereby making it difficult to target therapeutically. ...Further, drug resistance develops following use of many targeted monotherapies due to upregulation of compensatory signalling pathways. ...
Triple negative breast cancer (TNBC) is a complex and aggressive subtype of breast cancer which lacks oestrogen receptors, progesterone rece …
Discontinuing Long-Term PPI Therapy: Why, With Whom, and How?
Targownik L. Am J Gastroenterol 2018 - Review. PMID 29557943
Proton pump inhibitors (PPIs) are among the most widely used class of drugs prescribed over the long term in all of clinical medicine with 8-10% of ambulatory adults have been prescribed a PPI in the past 30 days. However, numerous studies have raised doubts about the long term safety of PPI use. The purpose of this review is threefold: (i) To provide an overview of the current evidence demonstrating associations between PPI use and adverse health outcomes and the likelihood of the associations being causal (Why?)...
Proton pump inhibitors (PPIs) are among the most widely used class of drugs prescribed over the long term in all of clinical medicine …
New Therapeutic Strategies for Triple-Negative Breast Cancer.
Székely B, et al. Oncology (Williston Park) 2017 - Review. PMID 28205193 Free article.
Relatively few clinically important therapeutic advances have occurred in the treatment of triple-negative breast cancer (TNBC) since the introduction of taxanes as adjuvant therapy over 20 years ago. However, this is rapidly changing due to a variety of conceptually important clinical trials and emerging new options such as immune checkpoint inhibitors and antibody-drug conjugates. ...
Relatively few clinically important therapeutic advances have occurred in the treatment of triple-negative breast cancer (TNBC) since …
Changes in Cancer Treatment: Mabs, Mibs, Mids, Nabs, and Nibs
Tariman JD. Nurs Clin North Am 2017 - Review. PMID 28189167
These therapeutic advances came largely because of improved understanding of the pathobiology of cancer at the genetic and molecular levels. This article addresses the need of novice nurses for cancer treatment-related information and evidence-based nursing care of patients diagnosed with cancer while undergoing novel and breakthrough therapeutics....
These therapeutic advances came largely because of improved understanding of the pathobiology of cancer at the genetic and molecular …
Cutaneous Adverse Events of Targeted Therapies for Hematolymphoid Malignancies
Ransohoff JD and Kwong BY. Clin Lymphoma Myeloma Leuk 2017 - Review. PMID 28918995
We include discussion of tyrosine kinase inhibitors (imatinib, dasatinib, nilotinib, bosutinib, ponatinib), blinatumomab, ibrutinib, idelalisib, anti-B cell antibodies (rituximab, ibritumomab, obinutuzumab, ofatumumab, tositumomab), immune checkpoint inhibitors (nivolumab, pembrolizumab), alemtuzumab, brentuximab, and proteasome inhibitors (bortezomib, carfilzomib, ixazomib). ...
We include discussion of tyrosine kinase inhibitors (imatinib, dasatinib, nilotinib, bosutinib, ponatinib), blinatumomab, ibrutinib, …
Proton Pump Inhibitors: What the Internist Needs to Know.
Spechler SJ. Med Clin North Am 2019 - Review. PMID 30466666
This report reviews the physiology of gastric acid suppression by proton pump inhibitors (PPIs) and anti-inflammatory effects of PPIs that are independent of their acid-suppressive effects. Valid indications for PPI use are discussed, as are putative adverse effects of PPIs that have been identified through weak associations in observational studies that cannot establish cause-and-effect relationships. ...
This report reviews the physiology of gastric acid suppression by proton pump inhibitors (PPIs) and anti-inflammatory effects of PPIs …
Chronic use of proton pump inhibitors, adverse events and potential biological mechanisms: A translational analysis.
Kheloufi F, et al. Therapie 2018 - Review. PMID 29128115
Proton pump inhibitors (PPIs) are among the most frequently prescribed drugs. Even if PPI are usually considered as safe, there is a growing concern for a range of adverse effects of chronic PPI therapy often in the absence of appropriate indications. ...Evidence that PPIs may have off-targets and pleiotropic effects are mounting and may impose a cautious attitude in the prescription of PPI's, especially in elderly and/or in the context of chronic use....
Proton pump inhibitors (PPIs) are among the most frequently prescribed drugs. Even if PPI are usually considered as safe, there is a …
154,252 results
Jump to page
Feedback